Jacobson Sandra A, Sabbagh Marwan N
Research Cleo Roberts Center for Clinical Research, Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ 85351, USA.
Expert Opin Drug Metab Toxicol. 2008 Oct;4(10):1363-9. doi: 10.1517/17425255.4.10.1363.
There is substantial evidence from preclinical studies that cholinesterase inhibitors affect basic processes that have been implicated in Alzheimer's disease (AD) pathogenesis, suggesting that these drugs should have both disease-modifying and neuroprotective effects in humans. The evidence seems to be strongest in relation to donepezil, which is the focus of this review.
To summarize the preclinical literature regarding the effects of donepezil on cellular and molecular processes underlying AD. Second, to suggest reasons for the apparent disparity between robust preclinical effects and modest clinical effects of this drug and others in its class.
Articles retrieved from PubMed searches were critically reviewed and selected for relevance to the current topic.
RESULTS/CONCLUSION: Donepezil has numerous cellular and molecular effects that should influence AD progression.
临床前研究有大量证据表明，胆碱酯酶抑制剂会影响与阿尔茨海默病（AD）发病机制相关的基本过程，这表明这些药物在人体中应具有疾病修饰和神经保护作用。与多奈哌齐相关的证据似乎最为确凿，多奈哌齐也是本综述的重点。
总结关于多奈哌齐对AD潜在细胞和分子过程影响的临床前文献。其次，指出该药物及同类其他药物在临床前效果显著与临床效果一般之间存在明显差异的原因。
对从PubMed检索到的文章进行严格审查，并根据与当前主题的相关性进行筛选。
结果/结论：多奈哌齐具有众多细胞和分子效应，应会影响AD的进展。
